Prescription Required
Formulation: ER Tablet
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: ER Tablet
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Rinvoq contains the active ingredient upadacitinib. It is a prescription medication used to treat several inflammatory and autoimmune conditions, including rheumatoid arthritis and psoriatic arthritis.
Rinvoq belongs to a group of medications called Janus kinase inhibitors, commonly known as JAK inhibitors.
Rinvoq is used to treat adults with moderately to severely active rheumatoid arthritis when one or more tumour necrosis factor inhibitors, also called TNF blockers, did not work well enough or could not be tolerated.
Rheumatoid arthritis is an autoimmune condition in which the immune system mistakenly attacks the lining of the joints. This can cause joint pain, swelling, stiffness, warmth, and difficulty moving.
Rinvoq may help reduce inflammation and relieve symptoms such as joint pain, swelling, tenderness, and morning stiffness. It may also help improve physical movement and daily functioning.
Rinvoq helps control rheumatoid arthritis, but it does not cure the condition.
Rinvoq is also used to treat active psoriatic arthritis in adults when one or more TNF blockers did not work well enough or could not be tolerated. It is also approved for certain children aged two years and older with active psoriatic arthritis under similar treatment circumstances.
Psoriatic arthritis is an inflammatory condition that can affect the joints, tendons, skin, and nails. Symptoms may include painful or swollen joints, morning stiffness, swollen fingers or toes, heel pain, and psoriasis-related skin changes.
Rinvoq may help reduce joint pain, inflammation, swelling, and stiffness. It may also improve physical function and help control other symptoms associated with psoriatic arthritis.
The immune system uses enzymes called Janus kinases to send signals that help control inflammation. In autoimmune conditions, some of these signals become overactive and contribute to ongoing inflammation and tissue damage.
Rinvoq blocks certain Janus kinase enzymes, particularly JAK1. This reduces the activity of inflammatory signals involved in rheumatoid arthritis and psoriatic arthritis.
By calming these overactive immune signals, Rinvoq may help reduce pain, swelling, stiffness, and other symptoms. It can also help slow some of the joint damage caused by uncontrolled inflammation.
Rinvoq affects the immune system and can reduce the body’s ability to fight infections. Your healthcare provider will evaluate you for infections, including tuberculosis, before treatment and monitor you while you take the medication.
Rinvoq is generally not recommended in combination with another JAK inhibitor, a biologic disease-modifying antirheumatic drug, or a strong immunosuppressant such as azathioprine or cyclosporine.
Take Rinvoq exactly as prescribed and attend all recommended appointments and blood tests so your healthcare provider can monitor the medication’s effectiveness and safety.
Rinvoq is an extended-release tablet taken by mouth once daily. You may take it with or without food.
Swallow the tablet whole with water. Do not crush, chew, split, or break it. Damaging an extended-release tablet can interfere with the way the medication is released into your body.
Take Rinvoq at approximately the same time every day. Choose a time that is easy to remember and follow your healthcare provider’s instructions carefully.
Do not take more than prescribed, change your dose, or stop treatment without first speaking with your healthcare provider.
Rinvoq may be taken with a meal or on an empty stomach. Food does not need to be timed around the dose.
However, you should avoid grapefruit and drinks containing grapefruit during treatment. Grapefruit can increase the amount of upadacitinib in your body and may raise the risk of side effects.
Ask your pharmacist if you are unsure whether a food, juice, or supplement contains grapefruit.
Available tablet strengths
Rinvoq extended-release tablets are available in several strengths, including:
The correct strength depends on the condition being treated, the treatment stage, your response, and your risk of side effects.
Do not assume that a higher strength will provide better results. Higher doses may carry a greater risk of infections and other serious adverse effects.
For adults with rheumatoid arthritis or psoriatic arthritis, the recommended dose is generally 15 mg once daily.
The 30 mg dose is not the usual dose for these conditions. Do not increase the dose unless your healthcare provider has prescribed it for a different approved condition.
The Rinvoq dosage varies significantly depending on the condition being treated.
For certain inflammatory bowel diseases, such as ulcerative colitis and Crohn’s disease, treatment usually begins with a higher induction dose for a limited period. This is followed by a lower maintenance dose once the condition is under better control.
A maintenance dose of 15 mg once daily is generally recommended for inflammatory bowel disease. A dose of 30 mg once daily may be considered for some patients with refractory, severe, or extensive disease when 15 mg does not provide an adequate response.
“Refractory” means that the condition has remained active or difficult to control despite appropriate treatment.
The lowest effective maintenance dose should be used. Rinvoq should be discontinued if an adequate response is not achieved with the 30 mg maintenance dose.
Different dosages may also be used for atopic dermatitis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and certain pediatric conditions. Always follow the dose prescribed specifically for your diagnosis.
Your healthcare provider may select or change your dose based on:
Certain medications can increase or decrease the amount of Rinvoq in your body. Tell your healthcare provider and pharmacist about all prescription medications, over-the-counter products, vitamins, and herbal supplements you use.
If you remember the missed dose later on the same day, take it as soon as possible.
If you do not remember until the following day, skip the missed dose and take your usual dose at the regular time.
Do not take two doses at the same time or take an extra tablet to make up for a missed dose.
The outer shell of an extended-release tablet may occasionally be visible in the stool after the medication has been released. This does not always mean that the dose was not absorbed.
However, contact your healthcare provider if you repeatedly notice what looks like an intact tablet or tablet fragments in your stool or ostomy output. Your healthcare provider may need to assess whether the medication is passing through your digestive tract too quickly.
Rinvoq affects the immune system. Before starting treatment, your healthcare provider may test you for tuberculosis, hepatitis, infections, anemia, low blood-cell counts, liver problems, and pregnancy when applicable.
Blood tests may be repeated during treatment to monitor:
Your dose may be temporarily interrupted if you develop a serious infection or significant blood-test abnormality.
Tell your healthcare provider about your vaccination history before starting Rinvoq. Recommended vaccines should ideally be brought up to date before treatment begins.
Live vaccines are generally avoided during Rinvoq treatment because the medication weakens certain immune responses. Ask your healthcare provider before receiving any vaccine.
Take Rinvoq exactly as prescribed and attend all scheduled follow-up appointments and blood tests.
Contact your healthcare provider promptly if you develop signs of an infection, such as fever, chills, persistent cough, shortness of breath, painful skin sores, burning during urination, or unusual tiredness.
Seek urgent medical attention for symptoms such as chest pain, sudden shortness of breath, swelling or pain in one leg, weakness on one side of the body, severe abdominal pain, or signs of a serious allergic reaction.
Rinvoq (Upadacitinib) is available in the following forms and strength:
Rinvoq affects the immune system and can reduce your body’s ability to fight infections. Using it with other medications that suppress the immune system may further increase the risk of serious infections.
Before starting Rinvoq, tell your healthcare provider about every prescription medication, over-the-counter product, vitamin, and herbal supplement you take. This is especially important if you use corticosteroids, methotrexate, biologic medications, another Janus kinase inhibitor, or another strong immunosuppressant.
Rinvoq is generally not recommended in combination with another JAK inhibitor, a biologic disease-modifying medication, or a potent immunosuppressant such as azathioprine or cyclosporine. Your healthcare provider will determine which treatments can be used together safely.
Rinvoq carries boxed warnings about blood clots, certain cancers, heart attack, stroke, serious infections, and an increased risk of death in some patients.
Before prescribing Rinvoq, your healthcare provider will consider your age, smoking history, previous blood clots, cancer history, and risk factors for heart disease or stroke. These risks may be especially important in adults aged 50 or older who have cardiovascular risk factors and in people who currently smoke or previously smoked.
The dose is not automatically reduced simply because a person has these risk factors. Instead, your healthcare provider will decide whether Rinvoq is appropriate, whether another treatment would be safer, and which approved dose should be used. When different maintenance doses are available for the condition being treated, the lowest effective dose should generally be selected.
Seek immediate medical attention if you develop chest pain, sudden shortness of breath, weakness on one side of your body, difficulty speaking, or pain, warmth, redness, or swelling in an arm or leg.
Rinvoq may harm an unborn baby and should generally not be used during pregnancy.
Your healthcare provider may perform a pregnancy test before treatment begins. People who can become pregnant should use effective birth control while taking Rinvoq and for four weeks after the final dose.
Tell your healthcare provider immediately if you become pregnant or think you may be pregnant during treatment.
Do not breastfeed while taking Rinvoq or for six days after your final dose. It is not known whether upadacitinib passes into human breast milk, but there may be a risk of serious side effects in a nursing infant.
Discuss feeding options with your healthcare provider before starting treatment.
Avoid grapefruit and grapefruit juice while taking Rinvoq. Grapefruit can increase the amount of upadacitinib in your body and may raise the risk of side effects.
Check drink labels and ask your pharmacist if you are unsure whether a food, beverage, or supplement contains grapefruit.
Alcohol is not listed as having a direct prohibited interaction with Rinvoq in the prescribing information. However, Rinvoq can affect the liver, and drinking alcohol may add to liver strain, particularly if you already have liver disease or take other medications that affect the liver.
Ask your healthcare provider whether alcohol is safe for you and whether you should limit or avoid it. Attend all recommended blood tests so your liver function can be monitored during treatment.
Take Rinvoq exactly as prescribed and do not change your dose or combine it with another immune-suppressing treatment without medical guidance.
Contact your healthcare provider promptly if you develop a fever, chills, persistent cough, painful rash, unusual tiredness, burning during urination, or another possible sign of infection. Treatment may need to be temporarily stopped if you develop a serious infection.
Rinvoq contains upadacitinib, a medication known as a Janus kinase inhibitor, or JAK inhibitor. JAK enzymes help transmit signals that activate inflammation within the body. In conditions such as rheumatoid arthritis, these immune signals become overactive and contribute to joint pain, swelling, stiffness, and tissue damage. Rinvoq blocks certain JAK enzymes, particularly JAK1. This helps reduce the inflammatory signals involved in autoimmune and inflammatory conditions. As inflammation decreases, symptoms such as pain, swelling, stiffness, and difficulty moving may improve. Rinvoq helps control inflammation, but it does not cure rheumatoid arthritis or other conditions for which it is prescribed.
Rinvoq extended-release tablets are usually taken by mouth once daily. The tablet may be taken with or without food. Swallow the tablet whole with water. Do not crush, chew, split, or break it because this may interfere with the way the extended-release medication is delivered. Take Rinvoq at approximately the same time each day. The appropriate dose depends on the condition being treated, your age, your response to treatment, and other health factors. Do not change your dose or stop taking Rinvoq without speaking with your healthcare provider.
Rinvoq can be taken with some medications, but certain combinations may increase the risk of infections or other serious side effects. Before starting Rinvoq, tell your healthcare provider and pharmacist about every prescription medication, over-the-counter product, vitamin, and herbal supplement you take. Rinvoq is generally not recommended with another JAK inhibitor, a biologic disease-modifying medication, or a strong immune-suppressing medicine such as azathioprine or cyclosporine. Combining these treatments may suppress the immune system too much and increase the risk of serious infections. Other medications can change the amount of upadacitinib in your body. Your healthcare provider may need to adjust your treatment or monitor you more closely. Do not start or stop another medication without medical guidance.
The amount of time Rinvoq takes to work varies depending on the condition being treated and how your body responds. Some people may notice improvement in symptoms within the first few weeks of treatment. For example, joint pain, swelling, or morning stiffness may begin to improve gradually. However, it may take several weeks or a few months to experience the medication’s full benefit. Continue taking Rinvoq exactly as prescribed, even if you do not notice an immediate improvement. Contact your healthcare provider if your symptoms do not improve, become worse, or you develop concerning side effects. Regular appointments and blood tests help determine whether Rinvoq is working safely and effectively.
| Generic name: | Upadacitinib |
|---|---|
| Formulation: | ER Tablet |
| Strength(s): | 30mg |
| Quantities Available: | 30 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Rinvoq (upadacitinib) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Rinvoq is commonly prescribed in dosages of 15 mg or 30 mg, taken once daily. For a 90-day supply, this means you would order 90 tablets (90 days x 1 tablet per day).
No, our website does not sell upadacitinib directly. However, you can still enjoy low prices on Rinvoq, which contains upadacitinib as an active ingredient. To purchase Rinvoq, you will need a valid prescription from your healthcare provider. We require this to dispense the medication. You can conveniently submit your prescription by mail, fax, or upload it through your online account to facilitate the ordering process.
Yes, we ship Rinvoq (upadacitinib) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Rinvoq (Upadacitinib). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Rinvoq (Upadacitinib).
REVIEWS